NEOGNeogen Corporation

Healthcare

$11.85+111% 1Y

$11.85

$5.3652 weeks$13.99

Price

+111%1Y

End-of-day closes, not the intraday tick.

Survival is the story here: start there

Quality mixed, hard red flags, demanding price, growth steady, the market undecided.

RyuScore 17 of 100: see how it is built

What they do

Neogen’s Animal Safety segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, insect control products and genomics testing services for the worldwide animal safety market. The majority of these consumable products are marketed through veterinarians, retailers, livestock producers and animal health product distributors.

In the company’s own words · 10-K filed Jul 30, 2026 · SEC EDGAR

P/En/a

Market value$2.07B

1 year+111%

5 years-72%

Charts

As reported to the SEC, without any scoring.

Neogen Corporation (NEOG) reported revenue of $225M in Q4 2026 (quarter ended May 31, 2026), down 0.1% from the same quarter a year earlier. That came with a gross margin of 48% and net loss of $11M. For the full year FY2026, revenue was $870M (−2.7% year on year) and net income −$7.9M. Its largest product in Q4 2026 was Bacterial And General Sanitation at $47M, 40% of the disclosed total, ahead of Service at 23%. The next results filing is expected around Jan 7, 2027, the same week as a year ago.

What the company said

The company's own words from its current reports to the SEC, newest first

Oct 6, 2026Neogen Reports First-Quarter Financial Results for Fiscal Year 2027.Earnings release · press release
Aug 7, 2026On August 3, 2026, Mr. Thierry Bernard resigned from the Board of Directors of Neogen Corporation.Director or officer change · Form 8-K
Jul 30, 2026Neogen Reports Fourth Quarter and Full Fiscal Year 2026 Financial Results.Earnings release · press release